Start with your stage, tumor subtype, exact biomarker result and prior treatment. A first-line metastatic trial, a trial after an EGFR inhibitor, and a study around surgery may enroll very different people—even when they use the same drug.
Answer a few questions to find clinical trials matched to your specific Non-Small Cell Lung Cancer situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Resectable or postoperative: studies may require enrollment before surgery, specific pathological stage, residual disease or a particular neoadjuvant regimen.
Unresectable stage III: studies during or after definitive chemoradiation differ from first-line metastatic trials.
Advanced or metastatic: first-line generally means no prior systemic treatment for that advanced setting. After-treatment studies can require a specific drug, documented progression and a new biomarker test.
Adenocarcinoma versus squamous: non-squamous-only protocols do not automatically include squamous NSCLC. Brain metastases may be required, allowed only if stable, or excluded depending on the protocol.
Current Clinical Trial Landscape
Registry snapshot, November 15, 2026: a worldwide ClinicalTrials.gov search for Non-Small Cell Lung Cancer, interventional studies, overall status Recruiting returned 1,089 records. This broad search result is not the number suitable for one person. Open the filtered registry search.
Selected research includes targeted therapies, ADCs, immunotherapy combinations, vaccines, radiation and local treatment. These categories overlap; no fresh class-specific totals are claimed.
Biomarker Results Are Not Interchangeable
EGFR: record the exact variant. Exon 19 deletion/L858R, exon 20 insertion and uncommon PACC mutations can lead to different studies. Firmonertinib NCT07185997 selects PACC mutations.
KRAS: G12C and G12D are different variants. RAS-multiselective protocols still define eligible mutations and prior-treatment cohorts.
ALK, ROS1, RET, NTRK and BRAF: bring the original fusion or mutation report; a gene name alone may not satisfy eligibility.
HER2: an activating ERBB2/HER2 mutation is different from protein overexpression measured by IHC. The mutation-selected and overexpression-selected examples below are separated.
MET: exon 14 skipping, amplification and c-Met protein overexpression are distinct findings. A c-Met ADC study does not necessarily require MET amplification.
PD-L1 and other tests: report the assay, TPS/other score and sample date. MTAP deletion, TROP2 or other expression requirements may be protocol-specific.
Selected Trials by Biomarker and Treatment Setting
All 77 cited registry records were checked November 15, 2026: 71 recruiting, three not yet recruiting, and three active but not recruiting. All examples below have a phase and dated recruitment label. The six non-enrolling studies are separated at the end. An overall recruiting label does not guarantee that a local site or specific cohort is open, or that you are eligible.
EGFR first-line advanced or metastatic disease
NCT06970639 — Furmonertinib plus platinum chemotherapy versus osimertinib for EGFR-sensitizing-mutant non-squamous NSCLC with brain metastases (Phase 3; recruiting).
NCT06350097 — Osimertinib with or without datopotamab deruxtecan first-line for EGFR exon 19 deletion/L858R disease; this is not a post-osimertinib study (Phase 3; recruiting).
NCT07005102 — Telisotuzumab adizutecan plus osimertinib first-line for classical EGFR-mutant non-squamous disease; c-Met IHC testing is required, not a general MET-amplified post-osimertinib cohort (Phase 2/3; recruiting).
NCT07185997 — Firmonertinib versus osimertinib or afatinib for selected uncommon EGFR PACC mutations, with no prior advanced-disease systemic treatment (Phase 3; recruiting).
EGFR after prior TKI treatment
NCT06927986 — SYS6010 versus platinum chemotherapy after EGFR-TKI failure in EGFR-sensitive-mutant advanced disease; mutation and prior-TKI sequence requirements apply (Phase 3; recruiting).
EGFR exon 20 insertion and selected uncommon-mutation studies
NCT07182682 — Adjuvant sunvozertinib versus placebo after radical surgery for early-stage disease with EGFR exon 20 insertion or selected PACC mutations (Phase 3; recruiting).
NCT06864624 — Sunvozertinib before and after surgery for stage II–IIIB EGFR exon 20 insertion NSCLC (Phase 2; recruiting).
NCT05967689 — Zipalertinib for advanced NSCLC with EGFR exon 20 insertion or other uncommon EGFR mutations (Phase 2; recruiting).
NCT07392658 — Amivantamab plus single-agent chemotherapy for platinum-unfit patients with EGFR exon 20 insertion NSCLC (Phase 2; recruiting).
NCT06816992 — ORIC-114 plus subcutaneous amivantamab for EGFR exon 20 insertion NSCLC (Phase 1; recruiting).
NCT06514027 — BEBT-109 for NSCLC with EGFR exon 20 insertion mutations (Phase 2; recruiting).
NCT06706713 — BEBT-109 for EGFR exon 20 insertion NSCLC; a separate protocol from NCT06514027 (Phase 2; recruiting).
NCT06043817 — First-in-human STX-721/PFL-721 for advanced NSCLC with EGFR or HER2 exon 20 insertion mutations (Phase 1/2; recruiting).
NCT03191149 — Osimertinib for selected EGFR exon 20 changes; investigational use does not imply all exon 20 variants respond like classical EGFR mutations (Phase 2; recruiting).
EGFR resectable, postoperative or limited-metastatic settings
NCT04853342 — Adjuvant furmonertinib versus placebo after complete resection of EGFR-mutant stage II–IIIA disease (Phase 3; recruiting).
NCT06041776 — Adjuvant befotertinib for stage IB–IIIB disease with EGFR-sensitive mutations (Phase 3; recruiting).
NCT07642024 — PANKU-Lung09: BL-B01D1 plus osimertinib around surgery for resectable EGFR-mutant disease (Phase 2/3; recruiting).
NCT07738172 — Osimertinib with or without primary lung-tumor surgery for EGFR-mutant oligometastatic disease (Phase 3; recruiting).
KRAS G12C first-line advanced or metastatic disease
NCT06875310 — KRYSTAL-4: adagrasib plus pembrolizumab and chemotherapy versus the same backbone with placebo in untreated non-squamous KRAS G12C disease (Phase 3; recruiting).
NCT06793215 — Divarasib plus pembrolizumab versus pembrolizumab plus platinum/pemetrexed in untreated advanced non-squamous KRAS G12C disease (Phase 3; recruiting).
NCT05920356 — CodeBreaK 202: sotorasib plus platinum-doublet chemotherapy versus pembrolizumab plus platinum-doublet chemotherapy in untreated non-squamous disease (Phase 3; recruiting).
NCT06119581 — Olomorasib plus pembrolizumab with or without chemotherapy for first-line advanced KRAS G12C disease (Phase 3; recruiting).
NCT06416410 — JAB-21822 plus the SHP2 inhibitor JAB-3312 versus standard care first-line for KRAS G12C disease (Phase 3; recruiting).
NCT07174908 — IN10018 plus D-1553 versus standard therapy first-line for non-squamous KRAS G12C disease (Phase 3; recruiting).
NCT04613596 — KRYSTAL-7: adagrasib alone or with pembrolizumab across study parts, including a Phase 3 combination comparison; cohort and PD-L1 requirements differ (Phase 2/3; recruiting).
NCT06345729 — KANDLELIT-004: calderasib plus pembrolizumab for KRAS G12C disease with PD-L1 TPS at least 50% (Phase 3; recruiting).
NCT07190248 — KANDLELIT-007: calderasib plus subcutaneous pembrolizumab versus subcutaneous pembrolizumab plus chemotherapy for advanced KRAS G12C disease (Phase 3; recruiting).
Other advanced KRAS and RAS-mutant studies
NCT06300177 — D-1553 versus docetaxel after standard therapy failure in KRAS G12C disease (Phase 3; recruiting).
NCT06881784 — RASolve 301: daraxonrasib for previously treated RAS-mutant NSCLC; the protocol defines eligible variants and prior treatment (Phase 3; recruiting).
NCT07566052 — Setidegrasib versus docetaxel for KRAS G12D disease (Phase 3; recruiting).
NCT07668752 — GFH375 versus docetaxel for previously treated KRAS G12D disease (Phase 3; recruiting).
NCT07777822 — Pembrolizumab/platinum/pemetrexed with or without zoldonrasib first-line for RAS G12D-mutant non-squamous disease (Phase 3; recruiting).
KRAS G12C postoperative or post-chemoradiation studies
NCT07431827 — Calderasib plus subcutaneous pembrolizumab versus placebo plus that pembrolizumab formulation after complete resection of stage IIA–IIIB (N2) disease; prior/perioperative treatment requirements apply (Phase 3; recruiting).
NCT06890598 — Olomorasib plus pembrolizumab in resected disease (Part A) or plus durvalumab in unresectable stage III without progression after concurrent chemoradiation (Part B) (Phase 3; recruiting).
NCT07554339 — KANDLELIT-015: calderasib plus durvalumab versus placebo plus durvalumab after definitive concurrent chemoradiation in unresected, predominantly non-squamous node-positive stage II–III disease (Phase 3; recruiting).
NCT07541170 — Adjuvant divarasib versus investigator-selected immunotherapy or observation after resection of KRAS G12C-positive stage II–III disease (Phase 3; recruiting).
NCT06564324 — Taletrectinib versus standard therapy for advanced ROS1-positive NSCLC (Phase 3; recruiting).
NCT07154706 — TRUST-IV: adjuvant taletrectinib versus placebo for ROS1-positive NSCLC (Phase 3; recruiting).
HER2 mutation-selected studies
NCT07178795 — BL-M07D1 versus pembrolizumab/platinum chemotherapy first-line for advanced non-squamous disease with centrally confirmed HER2 functional mutation (Phase 3; recruiting).
NCT07195695 — Beamion LUNG-3: adjuvant zongertinib versus standard treatment after complete resection of stage II–IIIB disease with activating HER2 kinase-domain mutations (Phase 3; recruiting).
NCT06452277 — Sevabertinib versus standard care first-line in advanced HER2-mutant disease (Phase 3; recruiting).
HER2 protein-overexpression-selected study
NCT06899126 — Trastuzumab deruxtecan plus pembrolizumab versus pembrolizumab plus platinum/pemetrexed first-line in HER2-overexpressing non-squamous disease, PD-L1 TPS below 50%, without a known HER2 mutation or locally targetable actionable driver; the experimental arm does not include chemotherapy (Phase 3; recruiting).
MET exon 14 and BRAF basket studies
NCT06908993 — Tepotinib versus standard treatment in previously treated advanced MET exon 14-mutated disease; this is distinct from MET amplification or c-Met protein overexpression (Phase 3; recruiting).
NCT05768178 — DETERMINE Arm 05: vemurafenib plus cobimetinib for actionable BRAF V600-mutant cancers; this is a basket study with master-protocol requirements, not a lung-only Phase 3 trial (Phase 2/3; recruiting).
First-line immunotherapy and combinations in advanced disease
NCT06627647 — Rilvegostomig or pembrolizumab plus chemotherapy for locally advanced/metastatic non-squamous disease (Phase 3; recruiting).
NCT06868277 — Rilvegostomig versus pembrolizumab alone for PD-L1-high metastatic disease (Phase 3; recruiting).
NCT06692738 — Rilvegostomig or pembrolizumab plus chemotherapy for advanced squamous disease (Phase 3; recruiting).
NCT06357533 — Datopotamab deruxtecan plus rilvegostomig first-line for non-squamous disease with PD-L1 at least 50% and no actionable genomic alteration (Phase 3; recruiting).
NCT06170788 — Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone in metastatic disease with PD-L1 TPS at least 50% (Phase 3; recruiting).
NCT06422143 — Pembrolizumab with or without maintenance sacituzumab tirumotecan in metastatic squamous disease (Phase 3; recruiting).
NCT06096844 — ACHIEVE: chemotherapy plus immunotherapy versus immunotherapy alone for selected older adults with stage IIIB–IV disease (Phase 3; recruiting).
NCT07365319 — EIK1001 plus pembrolizumab and chemotherapy for stage IV disease (Phase 2/3; recruiting).
NCT06980272 — SSGJ-707 versus pembrolizumab for advanced disease with PD-L1 TPS at least 1% (Phase 3; recruiting).
NCT07361510 — ROSETTA Lung-202: pumitamig versus pembrolizumab in untreated advanced disease with PD-L1 at least 50% (Phase 3; recruiting).
NCT07222566 — Symbiotic-Lung-01: PF-08634404 plus chemotherapy versus pembrolizumab plus chemotherapy for untreated advanced/metastatic squamous or non-squamous disease without locally actionable drivers; not a perioperative study (Phase 3; recruiting).
NCT06216301 — LUNAR-2: tumor treating fields plus pembrolizumab/platinum chemotherapy for metastatic disease; not stage III consolidation (Phase 3; recruiting).
NCT07063745 — Navlimetostat plus pembrolizumab/chemotherapy first-line for metastatic disease with homozygous MTAP deletion (Phase 2/3; recruiting).
Previously treated advanced disease: ADC, immunotherapy and gene-therapy approaches
NCT07291037 — Datopotamab deruxtecan versus docetaxel after prior treatment in TROP2-positive non-squamous disease without actionable genomic alterations (Phase 3; recruiting).
NCT07144280 — PF-08046054/SGN-PDL1V versus docetaxel in previously treated PD-L1-positive NSCLC; this is separate from sigvotatug vedotin (Phase 3; recruiting).
NCT06616584 — Cemiplimab added to usual treatment after platinum chemotherapy and immunotherapy (expanded Lung-MAP) (Phase 2/3; recruiting).
NCT07660094 — AURORA: aglatimagene besadenovec plus prodrug and pembrolizumab versus docetaxel for stage IV non-squamous disease progressing on pembrolizumab (Phase 3; recruiting).
Unresectable stage III or other locally advanced inoperable settings
NCT07361497 — ROSETTA Lung-201: pumitamig versus durvalumab after concurrent chemoradiation for unresectable stage III disease (Phase 3; recruiting).
NCT07131319 — Spatially fractionated radiotherapy plus tislelizumab/platinum chemotherapy for unresectable stage III disease (Phase 2/3; recruiting).
NCT05624996 — High-dose targeted radiation added to usual treatment for selected locally advanced inoperable disease; radiation and consolidation requirements apply (Phase 3; recruiting).
Resectable and postoperative immunotherapy or vaccine studies
NCT05487391 — QL1706 (iparomlimab/tuvonralimab, a two-antibody PD-1/CTLA-4 mixture) plus platinum chemotherapy after complete resection of stage II–IIIB disease (Phase 3; recruiting).
NCT06623422 — INTerpath-009: previously untreated resectable stage II–IIIB (N2) disease, with neoadjuvant treatment and surgery before postoperative intismeran/pembrolizumab randomization for residual disease; not a general post-surgery entry route (Phase 3; recruiting).
NCT07513376 — V940-014: adjuvant intismeran alone or with subcutaneous pembrolizumab versus placebo after surgery for selected high-risk stage I disease (Phase 3; recruiting).
NCT06312137 — MK-2870-019: adjuvant pembrolizumab with or without sacituzumab tirumotecan for resectable stage II–IIIB (N2) disease without complete pathological response after neoadjuvant pembrolizumab/chemotherapy (Phase 3; recruiting).
NCT07388524 — AASI-NSCLC: atezolizumab versus observation after complete resection of stage IA3/IB disease with PD-L1 TPS at least 50% and no EGFR exon 19 deletion/L858R or ALK fusion (Phase 3; recruiting).
Studies not open to new enrollment
NCT07183189 — SHR-A2009 plus aumolertinib versus aumolertinib first-line in EGFR-mutant advanced disease (Phase 3; active not recruiting).
NCT06417814 — Datopotamab deruxtecan with or without osimertinib versus platinum chemotherapy in EGFR-mutant advanced disease after prior EGFR treatment (Phase 3; active not recruiting).
NCT06077760 — V940-002: intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab in resected NSCLC (Phase 3; active not recruiting).
NCT07229339 — Zipalertinib plus carboplatin/pemetrexed for resectable stage II–IIIB disease (Phase 2; not yet recruiting).
NCT05767892 — YK-029A versus platinum chemotherapy first-line for EGFR exon 20 insertion disease (Phase 3; not yet recruiting).
NCT06380348 — JMT101 plus osimertinib versus cisplatin/pemetrexed for EGFR exon 20 insertion advanced disease (Phase 3; not yet recruiting).
Not yet recruiting means enrollment has not opened; active, not recruiting means ongoing treatment or follow-up without new enrollment. Check the current record and study team before making travel or treatment plans.
How do I find NSCLC trials for my stage and biomarker?
Bring your pathology, stage and latest scans, original mutation/fusion and protein-test reports, and exact prior treatments with dates and progression history. ClinTrialFinder suggests studies for discussion; a trial team confirms protocol eligibility and site availability.
How many NSCLC trials are recruiting?
The November 15, 2026 worldwide ClinicalTrials.gov query for Non-Small Cell Lung Cancer, interventional studies and Recruiting status returned 1,089 records. This is a broad registry search, not a personalized count. Of the 77 selected records on this page, 71 were recruiting; six were not open to new enrollment.
Are first-line trials available for advanced NSCLC?
Yes, selected examples include first-line targeted combinations for defined EGFR, ALK or KRAS groups and immunotherapy-based studies with histology, PD-L1 and driver-alteration restrictions. First-line metastatic treatment differs from treatment before or after surgery and from stage III consolidation.
Does an EGFR trial include all EGFR mutations?
No. Classical exon 19 deletion/L858R, exon 20 insertions and uncommon PACC mutations can have different eligibility requirements. Prior TKI exposure and resistance findings also matter. Read the specific variant and treatment-setting criteria rather than assuming EGFR-positive is enough.
Are HER2 mutation, HER2 expression and MET results equivalent?
No. HER2 activating mutation and HER2 IHC overexpression select different studies. MET exon 14 skipping, MET amplification and c-Met protein expression are also distinct. NCT07005102, for example, is first-line EGFR-mutant disease with c-Met IHC testing, not a general post-osimertinib MET-amplified cohort.
Can someone who already had surgery enter an adjuvant or vaccine trial?
It depends on the protocol. INTerpath-009 (NCT06623422) starts with previously untreated resectable disease and includes neoadjuvant treatment and surgery before postoperative randomization for residual disease. V940-014 (NCT07513376) instead studies selected high-risk stage I disease after surgery. The label adjuvant alone does not establish an entry route.
Find Lung Cancer Trials Matched to Your Situation
Enter your mutation type, PD-L1 status, and treatment history to get AI-matched trial results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.